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Abstract
A drug that is administered through a catheter into the bladder is referred to as an intravesical drug delivery system.
The aim of this work is to improvise intravesical drug delivery of Tacrolimus loaded lipid polymer hybrid nanoparticles
thermosensitive gel for bladder wall to provide control release, increase intravesical residence time and avoid fast
removal by urination. The Tacrolimus loaded lipid polymer hybrid nanoparticles mimic cell membrane and enhance
cellular uptakes. Our data reveals nanocarrier formation with a mean particle size, zeta potential and entrapment efﬁciency of optimal formula was found to be 124 ± 0.01 nm,-27.5 ± 0.102mv and 72% ± 0.15% respectively. In situ gelling
formulations containing TACeCSeLPHNs can adhere to the mucosal layer of the bladder and help in the diffusion of
therapeutic agent across the bladder wall. To impart mechanical strength and mucoadhesive properties, the chitosan
concentration was adjusted to 0.5% and 0.25%.The image of ﬁeld emission scanning electron microscope shows an
irregular surface with ﬁlled pores with nanoparticles. The gel was syringeable and had reasonable viscosity within room
temperature. A Tissue uptake study reveals that Tacrolimus loaded lipid polymer hybrid nanoparticles have been
penetrating bladder tissues and accumulated inside the cytoplasm and nucleus of urothelium epithelial cells. In addition, the bioimaging study shows that the gel resided inside the bladder for up to 2 h and completely urinated out of the
bladder with negligible distribution to other tissues.
Keywords: Tacrolimus, Intravesical drug delivery, Lipid polymer hybrid

1. Introduction

T

he effectiveness of drugs for local bladder
therapy depends on its ability to pass through
urothelium and physicochemical properties of the
drug itself, like the MWT (less than 200 Da),
lipid solubility and partition coefﬁcients [1].
Typically, approximately 50 mL of drug formulation may be instilled intravesically [2], and micturition is avoided for at least 1e2 h to ensure
successful drug transport into the underlying tissues [3]. Nevertheless, due to the presence of residual urine, drug formulation will be diluted and

wash out frequently [4]. Due to these limitations,
intravesical drug delivery can result in repeated
catheterization, frequent dosing, also may lead to
urinary tract infection and irritate the urinary
endothelium [5].
Advanced drug carriers have been designed to
enhance the solubility of hydrophobic drugs, the
diffusion of hydrophilic drugs through the urothelium, the adhesion of drug carriers to the urothelium, and the uptake/permeation of drugs into
bladder tissues over a prolonged period of time. An
example of these carriers are a Particulate incorporated hydrogel [7], modiﬁed nanoparticles, and
solubilized amphiphile [6].
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Hydrogel systems can act as drug depots,
increasing the residence time of drug in the bladder,
due to their bio-adhesion to the bladder mucosa [8].
A hydrogel that is particularly appealing is one
composed of injectable thermosensitive polymers
that form gels spontaneously at the target site. Due
to the fact that the body temperature is about 37  C,
thermosensitive gelation of the instilled polymeric
dispersion is likely to occur inside the bladder. Once
created inside the bladder, the hydrogel can act as a
matrix for drug delivery [9]. Poloxamer 407 is a
thermosensitive polymer. It is soluble in water up to
the lower critical solution temperature (LCST), but
transforms into a hydrogel above this point. Poloxamer 407 can be coupled with natural polymers
such as chitosan to enhance its mechanical strength
and mucoadhesive properties [10].
Bladder pain syndrome/Interstitial cystitis (BPS/
IC) is classiﬁed as a chronic inﬂammatory bladder
condition, hallmarked by the presence of chronic
pain. Interstitial cystitis is a life modifying disease
characterized by chronic pelvic and bladder pain,
frequent urination, and suprapubic pain [11]. The
main corner stone in the pathology of BPS/IC is the
destruction of the glycosaminoglycan (GAG) layer
[12].
Intravesical administration will help in providing
high drug concentration at the site of action and
eliminate the side effects associated with oral or
parenteral therapy, in addition to a small quantity of
drug that fractionated from the kidney to reaching
the bladder [12].
Chuang et al. study the effect of liposomal
encapsulated tacrolimus on the bladder of cyclophosphamide induced cystitis. He proposes that
Tacrolimus inhibited substantially the inﬂammatory
cystitis of cyclophosphamide by modifying the activity of IL2, PGE2 and EP4. These ﬁndings support
local tacrolimus research of inﬂammatory cystitis
refractory to conventional treatment [13].
The invention of such novel system which combines liposome and polymeric nanoparticles in
one nanoparticle results in major improvement in
drug delivery systems [3]. It is composed of three
distinct components, the polymeric core which is
mostly hydrophobic in nature, where the drug is
entrapped inside and the outer shell that is lipids in
nature and help in retarding the drug inside and
impart mechanical strength and control release [4].
The outer most layer is the lipid-PEG layer that
surround the lipid shell help in stabilization of the
nanoparticles by decrease the aggregation through a
steric hindrance also prolong in vivo circulation of
CS-LPHNs [5,6].

2. Experimental
2.1. Materials
Tacrolimus monohydrate was purchase from
Hangzhou Hyper Chemicals Limited (China).1,2distearoyl-glycero-3-phosphoethanolamine-N[methoxy
(polyethylene-glycol)-2000](DSPEPEG2000) and Soya bean phosphatidylcholine were
purchase from Avanti Polar Lipids, USA. Poly (D, Llactide-co-glycolide)
lactide:glycolide
(PLGA)
(75:25), mol wt 66,000e107,000 was purchased from
SigmaeAldrich, Chemie GMBH, Germany, Poloxamer 407 purchase from Prill, BASF, USA and
Chitosan LMW (MW 100000 Da; DD 98%) purchased from Giusto Faravelli, Milan, Italy. All the
other chemicals were of analytical quality.
2.2. Preparation of tacrolimus monohydrate loaded
lipid polymer hybrid nanoparticles
(TACeCSeLPHNs)
The preparation of TACeCSeLPHNs and characterization were described thoroughly in our previous article [26]. Brieﬂy, a self-assembly single step
nanoprecipitation method has been used. Organic
phase containing TAC and PLGA was dropped
using insulin syringe onto aqueous phase which
dissolving lecithin and DSPE-PEG2000 under magnetic stirring. The resulting solution was sonicated
for 3 min at frequency of 42 kHz and power of 50 W.
The unassembled component and the acetonitrile
were removed by washing TACeCSeLPHNs solution three times using an Amicon® Ultra-4 centrifugal ﬁlter unite (MWT 10000 Da) at rate 1000 rpm
which may resuspend again in deionized water to
obtain desired concentration. The resulting
TACeCSeLPHNs were stored at 4  C, or freeze
dried and lyophilized for storage at 20  C [14].
2.3. Preparation of TACeCSeLPHNs
thermosensitive mucoadhesive in situ gel
Using poloxamer 407 and low molecular weight
chitosan, a gel was prepared using the cold technique.
A calculated amount of TACeCSeLPHNs (each
7.2 mg equivalent to 1 mg TAC) was prepared as a
colloidal dispersed solution. Previous weighed
amount of poloxamer 407 was added for cold solution
of TACeCSeLPHNs (5e10  C) over 2e3 min under
magnetic stirring as in Table 1. Fast adding of the
powder to water should be avoided because it will
lead to formation of large ball which required many
hours to dissolve. A low MWT chitosan was dissolved
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Table 1. The formulas of TACeCSeLPHNs in situ gel.
Formula
Code

TACeCSe
LPHNs(mg)

Poloxamer
407 (wyw%)

Chitosan
(wyw%)

Deionized
water(g)

PX-1
PX-2
PX-3
PX-4

28.8
28.8
28.8
28.8

20
20
18
18

0.25
0.5
0.5
0.25

100
100
100
100

2.4.2. pH measurements
The pH value of the TACeCSeLPHNs in situ gel
was measured by means of pH 210 Microprocessor
pH Meter.

in 0.1 M HCl solution under magnetic stirring. Both
solutions were mixed in different ratio under stirring
for 15 min to obtain mixtures containing poloxamer
and chitosan as in Table 1. The pH was adjusted to
6.5. The ﬂuorescently labeled Gel was prepared by
using FITC-TACeCSeLPHNs instead of TACeCSe
LPHNs as seen in Fig. 1. Also, 6-Coumarin (6-C)
loaded in situ gel was prepared by using 6CeCSeLPHNs instead of TACeCSeLPHNs (see
Table 2).

2.4.3. Gelation temperature
Solegel transitions is an important parameter in
evaluating the formulations. 5 mL sample was taken
in a glass vial and was placed on a magnetic stirrer
(150 rpm) with the heating arrangement. The temperature was gradually increased at the rate of 2  C/
min. The temperature at which the rotation of the
magnetic bead was stopped was recorded as the
gelation temperature [15,16].

2.4. Characterization of TACeCSeLPHNs in situ gel
2.4.1. Field emission scanning electron microscope
(FESEM) analysis
The FESEM was performed to get a better understanding of TACeCSeLPHNs in situ gel
morphology and conﬁrm the particle size obtained
from DLS using Field Emission Scanning Electron
Microscope (FE-SEM), NovaNano SEM-600,
Netherlands.

2.4.4. Gelation time
The gelation time required for gel to transform
from a solution to gel state was determined at 37  C.
Vial inversion method has been used to determined
gelation time in the bladder environment. Brieﬂy,
5 mL of the sample was kept in glass vial and stored
in water bath at 37  C. The vial was inverted at a
speciﬁed time to test the gel ﬂow, and the time at
which the sample fails to ﬂow is described as the
gelation time [17].
2.4.5. Viscosity measurement
Viscosity is also one of the parameters to be
evaluated for in-situ gels. The viscosity of the formulations should be such that it remains convenient
during their administration by the patient. Viscosity
of the formulation was determined at different
temperature using Brookﬁeld viscometer, Brookﬁeld Engineering, USA [18,19].
2.4.6. Mucoadhesive strength
The mucoadhesive force was determined using
modiﬁed two-pan balance method. In vitro tests

Fig. 1. FITC-TACeCSeLPHNs in situ gel.
Table 2. The viscosity and gelation temperature of in situ gel after dilution.
Formula

Gelation temperature 
(C)

Viscosity (P.s.)




25 C

PX-1
PX-2
PX-3
PX-4

37 C

Before dilution

After dilution

240 ± 21.2
259 ± 8.12
1310 ± 12
700 ± 23.5

136
142
511
231

±
±
±
±

12.
22.
26.
10.7

Before dilution
67,000
98,000
48,000
44,000

±
±
±
±

23
34
28
56

After dilution
22,000
36,000
18,000
12,000

±
±
±
±

33
34
17
37

Before dilution

After dilution

26 ± 0.27
26.8 ± 0.1
25.5 ± 0.05
25 ± 0.19

27.3 ± 0.14
28 ± 0.17
26.4 ± 0.05
26.1 ± 0.21
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including two-pan balance method is the most common and convenient methods to assess the mucoadhesive properties of formulations. One side of the
balance was provided with an appropriate place for
the weight, and the other was designated for use as a
place for sheep's bladders. Gradually water added
drop by drop until the bladder tissue got detached
from the gel [20]. The weight of water necessary to
separate the two surfaces was calculated, and
mucoadhesion was found to be measured in grams.
F ¼ G*W
Where F is the muco-adhesion force (dynes/cm2).
W weight (grams).
G is the acceleration due to gravity (cm/s2).
2.4.7. Syringeability of formulations
Measurement with a syringe was used to determine the force done to extract the formulation was
accomplished using a texture analyzer (Stable Micro
Systems Ltd, UK) connected to a force sensor. The
gel was loaded in syringe that attached by urinary
catheter. The syringe pushed with a constant pressure at force of 0.5 N. The resistance to syringe
contents being expressed through the catheter
during plunger compression at 22  C [17].
2.4.8. Dilution of TACeCSeLPHNs in situ gel
Due to the presence of urine in the bladder,
dilution of the gel will happen and may affect
characteristics of the gel. 50 mL of in situ gel solution was diluted with an equal amount with 1:1 ratio
of artiﬁcial urine and evaluated for changes in gelling properties.
2.5. Animal studies and in vivo bioimaging
2.5.1. Animal welfare statement
All animal procedures performed in accordance
with ethical protocol approved by University of
Baghdad/Research Ethics Committee/ethical code

RECAUBCP112019 and conducted in Tehran university for medical science/preclinical core facility (TPCF).
2.5.2. Bladder instillation
Female mice were anesthetized with 100 mg/kg
and 10 mg/kg of ketamine and xylazine respectively,
then catheterized with a lubricated catheter of 24G
cannula. The bladders were emptied manually and
then irrigated with sterile PBS followed by the
installation of 50 mL of solution (6-CeCSeLPHNs in
situ gel). An ultra-small clamp was placed on the
external urethra for 2 h to prevent the bladder from
expelling its contents [21]. Fig. 2 reveal the installation of gel intravesically inside mouse bladder.
2.5.3. 6-CeCSeLPHNs uptake and retention by
bladders wall
Three female mice weighing 200 g was supplied
by the animal house. The solution then installed into
bladder as describe previously. One mouse was
injected with 50 mL of PBS as a control group and the
other was injected with 50 mL of 6-CeCSeLPHNs
after 2 h, the remaining TACeCSeLPHNs should
washed extensively with PBS before mice scariﬁed
and bladder extracted. The bladder wall was cut into
sections of 200 mm sections (thickness) and each of
these sections was applied to glass slides, where it
was ﬁxated using a wax and imaged by confocal
laser scanning microscope (CLSM) at 20X magniﬁcation [22].
2.5.4. Intravesical retention time and bioimaging
Twelve mice were shaved well before injected
intravesically because hair may have ﬂuorescence
emission and interfere with bioimaging study,
anesthetized and kept in room temperature.
The mice were classiﬁed into four groups and
bladder injected as the following.
A.Three mice was given PBS consider as the
control group and given code (I).
B. Six mice were injected with FITCeCSeLPHNs
solution and given code (II) and (III).

Fig. 2. Bladder installation for mice.
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C.Three
mice
was
injected
with
FITCeCSeLPHNs in situ gel and given code (IV).
The mice were visualized by kodak in vivo imaging system fx pro, KODAK, USA on predetermined
time (1,2,3,4,5,6 and 24hrs.) at 460 and 520 nm for
excitation and emission, respectively. Fluorescence
pictures were taken using Living Image 4.5.5 as seen
in Fig. 3.
2.5.5. Statistical studies
All experiments were repeated three times, and
data are presented as mean ± S.D. Statistical signiﬁcance was calculated using a two-way ANOVA
using Minitab program by setting the signiﬁcant as
level as p < 0.05.

3. Results and discussion
Intravesical drug delivery is a term that refers to
drugs that are administered via catheter into the
bladder. This local route of administration of
medication has been investigated for the treatment
of a variety of bladder disorders, including bladder
cancer, infection, and bladder pain syndrome [23].
The goal of this article is to improvise intravesical
drug delivery of TACeCSeLPHNs for bladder wall
to provide control release, increase intravesical
residence time and avoid fast removal by urination.
The TACeCSeLPHNs was prepared and characterized. The mean particle size, zeta potential and
entrapment efﬁciency of optimal formula was found
and discussed in separated article [26].
Certain polymers, such as poloxamer and chitosan, having thermosensitive and mucoadhesive in
situ gelling properties. Chitosan has the ability to
form non-covalent bonds with glycoprotein components of bladder mucin through electrostatic,
hydrogen bond and chain entanglement [24]. They
are preferred for design of intravesical drug delivery
system because can overcome some limitation of
this system like minimize bladder washout and
increasing residence time in bladder.
The
TACeCSeLPHNs-loaded
poloxamery
chitosan in situ gel, can create a bioadhesive gel
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layer over a large surface area of the urothelium,
enabling high concentrations of the drug to diffuse
for a prolonged period of time across urothelial
tissues. The common method used in laboratory to
prepare thermosensitive in situ gel refer as cold
method. Water was cooled for less than 10  C and
the poloxamer was added slowly over 20 min under
gentle stirring to help in hydration of the ﬂakes
surface with increase rate of dissolution and prevent
aggregation which may require several hours to
dissolved again. Due to weak mechanical properties
and rapid erosion of poloxamer 407, we added chitosan. The major limitation in use of chitosan in a
concentration more than 2% is increasing viscosity
of resulting gel [25]. Therefore, we use 0.5% and
0.25%, to impart mechanical strength and mucoadhesive properties.
The pH of the gel was adjusted to approximately
6.2, so it doesn't induce irritation in the bladder when
administered intravesically using 0.1 M NaOH.
3.1. Field emission scanning electron microscopy
Surface morphology of Intravesical gel was visualized using (FESEM). The image of gel shows
irregular surface with ﬁlled pores with nanoparticles
of drug which favored entry of water and release of
TACeCSeLPHNs as seen in Fig. 4.
3.2. Viscosity measurements
The viscosity of the gel may affect gel properties
like syringeability when injected through catheter
and spreadability in the bladder, for this reasons,
viscosity of the prepared formulation was evaluated
at different temperature using Brookﬁeld viscometer at different RPM and spindle number in order
to adjust the viscometer at higher desirability percentage. The result was showing in Fig. 5, the ﬁgure
reveals an increase in viscosity of the gel with an
elevation in temperature. Increase in the temperature will decrease in the viscosity of chitosan solution due to increase in thermal kinetic motion of
chitosan polymer. On the other hand, increase in

Fig. 3. Preparation and bladder installation of the mouse with in vivo imaging.
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Fig. 4. FESEM image of mucoadhesive thermosensitive in situ gel.

Fig. 5. The viscosity of formulated gels at different Temperatures.

the temperature lead to marked increase in viscosity
of poloxamer 407 solution due to thermo-gelling
properties of poloxamer [25]. From these observations, we can conclude that chitosan has a negative
effect on the viscosity of poloxamer-chitosan gel at
increasing temperature. Also, an increase in concentration of poloxamer 407 lead to increase the
viscosity of the gel. This result is desirable for
bladder formulation as the temperature of the body
will increase viscosity of the gel.

Data show signiﬁcant (P < 0.05) increase in the work
of compression in compare with NaCl solution. Also,
concentration of chitosan shows insigniﬁcant changes
in work of compression when comparing PX-1with
PX-2 while PX-4 shows a signiﬁcant (P < 0.05)
decrease in work when compare with PX-1. Increase
in the concentration of poloxamer polymer cause
signiﬁcant (P < 0.05) increase in the syringeability
work force required for injection.

3.3. Syringeability
Syringeability is a valuable test for evaluating
intravesical dosage form. Since the administration
of intravesical dosage form through the catheter, it
is crucial for poloxamer-chitosan in situ gel to pass
through the catheter freely and at the temperature
(22  C).
Figure 6 reveals the work required for injection of in
situ gel in the catheter through syringe, that inversely
related with syringeability through urinary catheter.

Fig. 6. Syringeability of TACeCSeLPHNs loaded in situ gel.
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3.4. Gelation temperature/Solegel transition
temperature (Tsol-gel)

Fig. 7. Tsol-gel of poloxamer-chitosan in situ gel formulas.

Force of detachemnet (N)

0.12
0.1
0.08
0.06
0.04

Phase transition temperature (Tsol-gel) is the temperature at which the liquid converted into gel and
consider as important parameter for in situ gel. The
optimal Tsol-gel should be between 25  C (the room
temperature and 35  C close to (body temperature).
The Tsol-gel of different poloxamer-chitosan in
situ gel formulas was shown in Fig. 7. It obvious
from the ﬁgure that Tsol-gel affected by polymer
concentration, as increase in concentration reduce
Tsol-gel, in addition to that chitosan concentration
shows little effects on Tsol-gel.
Because that gelling mechanism of poloxamer is
depending on the micelle packing and entanglements, the addition of drug or other polymer can
affect micelle formation and may modify Tsol-gel.
3.5. Dilution of TACeCSeLPHNs in situ gel

0.02
0
PX-1

PX-2

PX-3

PX-4

Due to incomplete empty of bladder, there is
about 50 mL of urine will stay as residual volume in
the bladder even after voiding that lead to dilution

Fig. 8. Mucoadhesion force of poloxamer-chitosan in situ gel formulas.

Fig. 9. Confocal laser scanning microscope images for cross-section of bladder tissues after treated with 6-CeCSeLPHNs in situ gel for 2 hrs.
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of in situ gel and change in its properties. Generally,
the in situ gel was administered by catheter in a
volume of 50e100 mL. Therefore, 50 mL of in situ
gel was diluted with 50 mL of artiﬁcial urine (1:1)
and the changes in properties were studied the results were shown in Table 2.
There is a signiﬁcant (P < 0.05) loss of viscosity
after dilution especially at 37  C and increase Tsol-gel
due to decrease in concentration of polymer.
3.6. Gelation time
All poloxamer-chitosan formulas show fast and
complete gelling with in physiological temperature
37  C. Figure 8 reveals the time required for gelling
(see Figs. 9,10).

A signiﬁcant increase (P < 0.05) in gelation time
was indicated with decrease in poloxamer concentration while a signiﬁcant increase in gelation temperature was detected with increase chitosan
concentration.
3.7. Animal studies and in vivo bioimaging
3.7.1. 6-CeCSeLPHNs uptake and retention by
bladders wall
We tried to develop a nanoparticle system which
have the ability to penetrate the bladder urothelium
and pass to underlying tissue in order to targeted
the drug to the site of action.
In this experiment, we treated the mouse with 6CeCSeLPHNs in situ gel, a ﬂuorescence material
that after taken up by the bladder wall it may be

Fig. 10. In vivo ﬂuorescence imaging of FITCeCSeLPHNs treated mice. (Mice 1 treated with PB, mice 2 and 3 treated with FITCeCSeLPHNs and
mouse 4 treated with FITCeCSeLPHNs in situ gel).

MA'AEN JOURNAL FOR MEDICAL SCIENCES 2022;1:13e23
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Fig. 10. (Continued).

visualized using confocal laser scanning. Images from
CLSM are seen in Fig. 9. Pictures reveals penetration
of nanoparticles of all bladder tissues starting with
mucosa passing through lamina propria and detrusor
muscle and even Adventitia penetrated by 6-C
nanoparticles. We may suggest that CS-LPHNs can
be used to deliver the drug for bladder layers.
Also, images reveal distribution of nanoparticles
inside the cytoplasm, nucleus and intracellular
junction.
3.7.2. In vivo ﬂuorescence imaging
In order to investigate the potential of such hybrid
system as the intravesical drug delivery system for
in vivo drug delivery. FITC was used as ﬂuorescence
probe for detection of hybrid nanoparticles inside
the body. Twelve mice taken these hybrid nanoparticles (FITC-TACeCSeLPHNs) intravesically,

and the ﬂuorescence were measured at a different
time interval. The mouse that have (code I) given
PBS and consider as control groups.
Six mice were given with FITC-TACeCSeLPHNs
solution (having the code II and III). Picture in
Fig. 10 show that solution stay for at least 2 hrs in the
bladder and successfully urine out of the bladder,
and still little ﬂuorescence intensity in the bladder
area up to 4 hrs which may be attributed to the
bladder tissue uptake of FTICeCSeLPHNs, also, it
doesn't show any body distributions to other organs.
Three mice were given the FITC-TACeCSe
LPHNs in situ gel intravesically. Few minutes after
injection, the gel shows a spherical shape red dot
inside the bladder which indicated the gel formation
which start dissolution and pushed out of the
bladder gradually up to 3 hrs as seen in Fig. 10. Thus
we can conclude that the residence time of the gel in
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the bladder was between 2 and 3 hrs and doesn't
interfere with the urination process.
The ﬂuorescence activity that seen in the head of
the mice due to the hair that doesn't shaved as the
whole body.

[5]

[6]

4. Conclusion
Bladder pain syndrome remains challenging for
treatment due to barriers and limitations of urinary
bladder like frequent urination and low penetration
capability. Tacrolimus loaded CS-LPHNs may
enhance the uptake of Tacrolimus by bladder tissue
due to the cell membrane like property. The incorporation
of
TAC-LPHNs
inside
PoloxameryChitosan thermosensitive in situ gel
increased the time of occupancy in the bladder.
CLSM images show the retention of dye (coumarin
6) inside the bladder tissue after 2 h of installation.
The gel shows a spherical shape red dot inside the
bladder which indicated the gel formation and start
to dissolute and pushed out of the bladder gradually
up to 3 hrs. Thus we can conclude that the residence
time of the gel in the bladder is between 2 and 3 hrs.
And doesn't interfere with the urination process.
Data show that PX-4 have the least viscosity and
work of compression required for injecting the formula inside the bladder and thus may be consider
as a selective formula.

[7]

[8]

[9]
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